Salute e Benessere

Cardiovascular, Renal & Metabolic (CRM) Diseases Market to Reach USD 451.87…

The upward trajectory in the CRM market is underpinned by several measurable factors: The upward trajectory in the CRM market is underpinned by several measurable factors: Download PDF Brochure:https://www.datamintelligence.com/download-sample/cardiovascular-renal-metabolic-diseases-market Browse in-depth TOC on 'Cardiovascular, Renal & Metabolic Diseases Market' 70 – Tables 66 – Figures 195 – Pages Market Segmentation: Detailing Key Growth Vectors By Disease...
PR Newswire
30/10/2025

Global Condom Market to Grow at 8.9% During 2026-32, Driven by Rising Awareness…

Download a FREE PDF Sample of the Report: https://www.marknteladvisors.com/query/request-sample/condom-market.html (Discover the market potential, platform-specific insights, and key industry trends.) Download a FREE PDF Sample of the Report: https://www.marknteladvisors.com/query/request-sample/condom-market.html(Discover the market potential, platform-specific insights, and key industry trends.) Global Condom Market size was valued at around USD 14.2 billionin 2025and is...
PR Newswire
30/10/2025

Cystic Fibrosis (CF) Therapeutics Market to Reach $17.1 billion by 2027 in the…

Request Sample of the Report on Cystic Fibrosis (CF) Therapeutics Market Forecast 2034 – https://www.alliedmarketresearch.com/request-sample/5499 Request Sample of the Report on Cystic Fibrosis (CF) Therapeutics Market Forecast 2034 –https://www.alliedmarketresearch.com/request-sample/5499 Market Introduction The cystic fibrosis (CF) therapeutics market focuses on the development and commercialization of treatments designed to manage and alleviate the symptoms of CF, a genetic...
PR Newswire
30/10/2025

Competitive Landscape of Obesity Therapeutics Market Enters High-Growth Phase…

Browse in-depth TOC on 'Competitive Landscape of Obesity Therapeutics Market' Browse in-depth TOC on 'Competitive Landscape of Obesity Therapeutics Market' 70 – Tables 66 – Figures 195 – Pages Competitive Landscape According to DataM Intelligence, key players in the obesity therapeutics market include:AstraZeneca,Rhythm Pharmaceuticals, Inc.,Takeda Pharmaceutical Company Limited, andKVK Tech, Inc.These firms are operating alongside dominant GLP-1 companies and...
PR Newswire
30/10/2025

Veterinary Biologics Market worth $3.51 billion by 2030 with 5.2% CAGR |…

Browse in-depth TOC on 'Veterinary Biologics Market'312 - Tables61 - Figures316 - Pages Browse in-depth TOC on 'Veterinary Biologics Market' 312 - Tables 61 - Figures 316 - Pages By product type,monoclonal antibodies are expected to register a high growth rate in the veterinary biologics market, driven by their targeted mechanism of action, high efficacy, and increasing adoption in livestock health management. These biologics are increasingly used to prevent and treat specific...
PR Newswire
30/10/2025

Signant Health Appoints Internationally Recognized Cognitive Assessment Expert…

John will work closely with Signant's David Miller, a renowned expert in Alzheimer's and other dementias and co-author of the ADAS-Cog scoring manual, to strengthen the company's cognitive assessment capabilities. His role will focus on driving innovation in clinical outcome assessments for CNS trials, with particular emphasis on Alzheimer's disease, dementia, and complex neurological conditions where cognitive endpoints play a central role in regulatory decision-making. John will work…
PR Newswire
30/10/2025

Hoag selects Philips to enhance and unify patient monitoring, elevating care…

10-year collaboration aims to connect scalable monitoring technology that streamlines workflows, supporting patient safety and the patient and clinician experienceAmsterdam, the Netherlands and Newport Beach, Calif., USA–Royal Philips(NYSE: PHG, AEX: PHIA), a global leader in health technology, andHoag, Orange County, California’s highest-ranked hospital, today announced a landmark 10-year strategic collaboration. The initiative will standardize and modernize patient monitoring...
Nasdaq GlobeNewswire
30/10/2025

Evaxion raises $7.2 million, extending cash runway to second half of 2027

Gross proceeds from sales of shares amounting to $4.5 million and exercise of warrants providing a further $2.7 millionTotal gross inflow of cash of $14.7 million since the end of the second quarter 2025Evaxion now has cash on hand to fund its operations and R&D programs into the second half of 2027The exercises have reduced the number of outstanding warrants to purchase Evaxion American Depositary Shares (ADSs) by 1.0 millionCOPENHAGEN, Denmark, October 30, 2025 -...
Nasdaq GlobeNewswire
30/10/2025

T-knife Therapeutics Announces Four Upcoming Data Presentations on…

-- Posters will review product characterization and manufacturing data on T-knife’s lead program, TK-6302, a supercharged PRAME T cell receptor therapy that is advancing towards the clinic, with the filing of a Clinical Trial Application planned in Q4 2025 -- PRAME is a validated target and is expressed in cancers of the skin, uterus, ovaries, lungs, breasts, esophagus, kidneys, cervix, and head & neck SAN FRANCISCO and BERLIN, Oct.30, 2025(GLOBE NEWSWIRE) -- T-knife...
Nasdaq GlobeNewswire
30/10/2025

OrganOx Completes Acquisition by Terumo Corporation to Advance the Future of…

$1.5 billion acquisition strengthens global leadership in organ technology and accelerates progress toward making every organ count As first announced on August 25, 2025, the acquisition combines OrganOx’s pioneering organ perfusion technology with Terumo’s global scale and expertise in medical innovation. “The global need for donor organs remains urgent, with thousands of patients each year dying while waiting for a transplant or facing the risk of a failed transplant,” said Craig...
Nasdaq GlobeNewswire
30/10/2025

Cambridge Atomworks is delighted to announce the appointment of Mr Alistair…

Ian Farnan, CEO, said, “We are excited to welcome someone with Alistair’s commercial and financial experience to the Board of Cambridge Atomworks. His expertise and knowledge will be invaluable as Cambridge Atomworks continues its ambitious growth plans.” About Cambridge Atomworks Cambridge Atomworks was set up in January 2023 as a consulting partnership to develop the design of ODIN, a Transportable Nuclear Micro-Reactor using a low pressure coolant. In August 2023, Cambridge...
Nasdaq GlobeNewswire
30/10/2025

Intraoperative Radiation Therapy Market to Double by 2030 Driven by Precision…

Recent Industry Developments (2024–2025) Recent Industry Developments (2024–2025) Download PDF Brochure:https://www.datamintelligence.com/download-sample/intraoperative-radiation-therapy-market Browse in-depth TOC on "Intraoperative Radiation Therapy Market" 76 – Tables 69 – Figures 194 – Pages Growth Drivers: Precision Oncology Meets Surgical Efficiency The adoption of IORT is accelerating due to its proven ability to deliver concentrated radiation doses...
PR Newswire
30/10/2025

Sales of Leqembi® totaled 18 billion yen in the third quarter 2025

This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on October 30, 2025, at 11:00 a.m. CET. This information is information that BioArctic AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact person below, on...
PR Newswire
30/10/2025

Novo Nordisk submits proposal to acquire Metsera, Inc.

Bagsværd, Denmark, 30 October 2025– Novo Nordisk confirms that it submitted an unsolicited proposal to acquire Metsera, Inc. (Metsera).The acquisition of Metsera, including its early and development-stage incretin and non-incretin analogue peptide programmes, would provide Novo Nordisk the opportunity to maximise the potential of Metsera’s complementary portfolio and capabilities. An acquisition would be in line with Novo Nordisk’s long-term strategy of developing innovative and...
Nasdaq GlobeNewswire
30/10/2025

Alys Pharmaceuticals doses first subject in Phase 1/1b trial of ALY-301, a…

Professor Martin Metz, Professor of Dermatology at the Institute of Allergology at the Charité – Universitätsmedizin Berlin & Fraunhofer Institute for Translational Medicine and Pharmacology, Allergology and Immunology and Principal Investigator for ALY-301, commented: "Chronic Urticaria is a disease where the burden on patients is often underestimated. ALY-301's ability to selectively target and deplete mast cells over other c-Kit positive cells, while potentially matching the efficacy…
PR Newswire
30/10/2025

Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor…

Oculis intends to use the net proceeds from the financing to advance and accelerate the development of its novel neuroprotective clinical candidate, Privosegtor in acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION), as well as for working capital and general corporate purposes.The financing consists of an underwritten offering (the “Underwritten Offering”) of 4,691,358 ordinary shares and a registered direct offering to an investor of 740,740 ordinary...
Nasdaq GlobeNewswire
30/10/2025

Nippon Gases Targets Greater Resilience and Increased Uptime with Multi-Site…

Nippon Gases is one of the leading industrial and medical gases companies in Europe. Its operations cover the supply of gases – in various physical forms and purities – including oxygen, nitrogen, argon, carbon dioxide, hydrogen, helium, carbon monoxide, and the services and technologies associated with the use of gases and mixtures. Nippon Gases is one of the leading industrial and medical gases companies inEurope. Its operations cover the supply of gases – in various physical forms and...
PR Newswire
30/10/2025

DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting

DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT – CUSIP: 23306J309), a clinical-stage biopharmaceutical company, today announced upcoming participation in the American College of Allergy, Asthma & Immunology (ACAAI) 2025 Annual Scientific Meeting, November 6 - 10, in Orlando, Florida. DBV will host a Product Theater titled“Harnessing Immune Plasticity to Alter the...
Nasdaq GlobeNewswire
30/10/2025

Pharming Group to participate in Fireside Chat at Jefferies Global Healthcare…

Leiden, the Netherlands, October 30, 2025:Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the Jefferies Global Healthcare Conference in London, UK, on November 17-20, 2025.Fabrice Chouraqui, Chief Executive Officer, will participate in a Fireside Chat Q&A session on Wednesday, November 19 at 10:00 GMT/11:00 CET. A live webcast and replay of the presentation can be found in the “Upcoming Events” and...
Nasdaq GlobeNewswire
30/10/2025

Boehringer Ingelheim acquires license from Kyowa Kirin aimed at developing a…

The licensed small molecule program aims to address significant unmet needs forautoimmune diseases . Programadds toBoehringer’s pipeline and its commitment to deliver breakthrough therapies for patients with inflammatory diseases . Ingelheim, Germany, and Tokyo, Japan ,[October 30 , 2025]–Boehringer Ingelheim and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151, President and COO: Abdul Mullick) today announced that Boehringer Ingelheim has...
Nasdaq GlobeNewswire
30/10/2025

Hansa Biopharma Reports Third Quarter and Interim Year to Date 2025 Financial…

Financial Performance Financial Performance Year to date IDEFIRIX product sales totalled 143.6 MSEK and represented an increase of 29.1 MSEK or 25.4% compared to the same period a year ago (114.5 MSEK). Year to date product sales represent approximately 102% of total full-year product sales achieved in 2024. Product sales in the third quarter of 2025 totalled 30.1 MSEK, compared to 39.8 MSEK for the same period in 2024. Lower sales numbers in the third quarter are largely driven by...
PR Newswire
30/10/2025

Roche purchases shares in tender offer for 89bio, Inc

Citibank, N.A., the depositary for the tender offer, advised Roche that a total of approximately 94,113,710 shares of 89bio’s common stock were validly tendered and not validly withdrawn in the tender offer (excluding shares tendered by notice of guaranteed delivery for which certificates have not yet been “received”), which represent approximately 60.49% of the total number of shares of 89bio’s common stock outstanding.Later today, Roche intends to complete the acquisition of 89bio...
Nasdaq GlobeNewswire
30/10/2025

QUVIVIQ sales up >130% driving Idorsia toward profitability – 9M 2025 results

Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ (daridorexant) global net sales (excluding sales to partners) increased by >130% year-on-year to CHF 91 million in 9M 2025 – continuing Idorsia’s trajectory towards profitabilityAprocitentan (TRYVIO/JERAYGO) the first and only dual ERA indicated for systemic hypertension and the only new medicine to be included in the ACC/AHA Hypertension Management guidelinesOperating cash runway extended beyond profitability into 2028 following CHF 65...
Nasdaq GlobeNewswire
30/10/2025

Piramal Pharma Solutions Formalizes Partnership with IntoCell, Expanding its…

Additionally, this agreement strengthens ADCelerate™, Piramal's rapid, integrated approach to bioconjugate development and manufacture. Utilizing IntoCell's existing resources allows Piramal to further streamline the path from concept to clinic. Additionally, this agreement strengthens ADCelerate™, Piramal's rapid, integrated approach to bioconjugate development and manufacture. Utilizing IntoCell's existing resources allows Piramal to further streamline the path from concept to clinic...
PR Newswire
30/10/2025
Altri  Comunicati